--- title: "MedPal AI plc – From zero to £28 million annualised in ten months" publisher: "Share Talk" author: "sharetalk" published: "2026-09-07T07:35:58+00:00" modified: "2026-09-07T07:35:58+00:00" date: 2026-09-07 canonical: "https://www.share-talk.com/medpal-ai-plc-from-zero-to-28-million-annualised-in-ten-months/" category: "Health" categories: ["Health", "Healthcare", "Pharmaceutical"] tags: ["blood testing", "Eli Lilly", "eMARx", "Foundayo", "Jason Drummond", "Juno", "MedPal AI plc", "MedPal Health OS", "MPAL", "NHS pharmacy services", "oral GLP-1 treatment", "private prescription"] image: "https://i0.wp.com/www.share-talk.com/wp-content/uploads/2026/09/1557a7e7-d0c0-42c0-895f-9c45030e6de3.png?fit=1727%2C911&quality=80&ssl=1" format: "news" language: "en-GB" --- # MedPal AI plc – From zero to £28 million annualised in ten months **Published:** September 7, 2026 **Author:** sharetalk **Categories:** Health, Healthcare, Pharmaceutical **Tags:** blood testing, Eli Lilly, eMARx, Foundayo, Jason Drummond, Juno, MedPal AI plc, MedPal Health OS, MPAL, NHS pharmacy services, oral GLP-1 treatment, private prescription **Featured image:** ![](https://i0.wp.com/www.share-talk.com/wp-content/uploads/2026/09/1557a7e7-d0c0-42c0-895f-9c45030e6de3.png?fit=1727%2C911&quality=80&ssl=1) --- [MedPal AI plc (AIM: MPAL)](https://www.investegate.co.uk/announcement/rns/medpal-ai-plc--mpal/august-trading-update/9757541) has reported a sharp acceleration in trading, with its New Health GLP-1 weight-management business generating **£1.83 million of revenue in August**, an increase of more than 800% from July. [!\[\](https://i0.wp.com/www.share-talk.com/wp-content/uploads/2026/08/9d813487-b6a0-4993-9746-fdae7efde578.png?resize=467%2C246&quality=80&ssl=1)](https://www.share-talk.com/medpal-ai-connects-pharmacy-private-care-and-software-in-a-rapid-growth-strategy/) [MedPal AI Connects Pharmacy, Private Care and Software in a Rapid Growth Strategy](https://www.share-talk.com/medpal-ai-connects-pharmacy-private-care-and-software-in-a-rapid-growth-strategy/) August was the first full month of trading for New Health following the launch of marketing in July, with the business processing **14,487 orders during the month**. Based on August’s performance, New Health is operating at an **annualised revenue run rate of approximately £21.9 million**, while MedPal’s three recurring revenue streams collectively reached an annualised run rate of approximately **£28 million**. The company stressed that annualised figures simply represent monthly revenue multiplied by 12 and **should not be regarded as forecasts**. ## Highlights - **New Health August revenue reached £1.83 million**, up 809% from £201,203 in July. - Revenue has increased more than **100-fold in two months**, from £15,496 in June. - New Health processed **14,487 orders during August**. - More than **16,000 customers have purchased through New Health** since its June launch. - New Health’s August performance equates to an annualised revenue run rate of approximately **£21.9 million**. - MedPal’s overall annualised run rate has increased from **£5 million in June to £8.6 million in July and approximately £28 million in August**. - Management says the growth has been generated **organically through trading rather than through the acquisition of an existing customer base**. - New Health operates at an estimated **25% gross margin** following its introductory offer period. - MedPal says its NHS dispensing operations generate gross margins above **27%**, while its eMARx care-home software generates approximately **82% gross margins**. - The group is targeting three major healthcare markets: **NHS prescriptions, care-home medicines management and private GLP-1 weight management**. ## New Health Revenue Tops £1.8m in First Full Month New Health generated **£1,828,319 of revenue from 14,487 orders in August**, compared with £201,203 in July and just £15,496 in June. That represents month-on-month growth of **809%** and means revenue has increased by more than 100 times in the space of two months. Since launching in June, New Health has attracted **16,051 purchasing customers**, according to MedPal. The company emphasised that the customer base has been built organically rather than purchased through acquisitions. MedPal said the entire increase from an £8.6 million annualised group revenue run rate in July to approximately £28 million in August resulted from trading. ## Three Recurring Revenue Streams MedPal is building its healthcare business around three areas which management believes have significant recurring-revenue characteristics. Its NHS pharmacy operations benefit from repeat prescription dispensing, while New Health customers typically receive treatment through monthly weight-management programmes. The group’s eMARx electronic medication administration platform, meanwhile, generates recurring monthly software subscription revenue from care-home customers. Management believes integrating these businesses could create opportunities to generate several revenue streams from individual customers while using its technology and automated dispensing infrastructure to control operating costs. ## Targeting a Multi-Billion-Pound GLP-1 Market Private weight management represents one of MedPal’s largest immediate opportunities. The company cited research estimating that around **1.6 million adults in Great Britain** had used GLP-1 or GLP-1/GIP medicines for weight loss during the year to early 2025. At private treatment costs of approximately £150 per month, MedPal estimates this could represent a potential market exceeding **£2.8 billion annually**. New Health’s gross margin is currently estimated at approximately **25% after its introductory offer period**, with customer acquisition costs recognised in the month they are incurred. ## NHS and Care Homes Offer Further Growth MedPal is also targeting the much larger NHS prescription market. Around **1.3 billion prescription items were dispensed in the community in England during 2025/26**, at a total cost of £11.6 billion. MedPal says its robotic dispensing hubs currently generate gross margins above 27% on NHS prescriptions and retain capacity to process additional volumes. The company is also targeting Britain’s approximately **500,000 care-home residents** through a combination of pharmacy dispensing, its eMARx medication-management platform and its Juno AI health companion. MedPal estimates the NHS spends approximately £500 million annually on medicines for UK care-home residents. ## CEO: “It Is Only the Beginning” Founder and chief executive **Jason Drummond** said August represented the month when the company’s strategy began to come together, with New Health exceeding management’s expectations. He highlighted the combination of prescribing, dispensing, delivery, administration and AI-enabled patient support as central to MedPal’s strategy. Drummond said the objective is ultimately to create a model where **one customer can generate multiple recurring revenue streams** across the group’s healthcare platform. With New Health moving from just **£15,496 of monthly revenue in June to £1.83 million in August**, the next key test will be whether MedPal can sustain customer acquisition and recurring monthly treatments at anything approaching the pace achieved during its first full month of marketing. --- **Original URL:** https://www.share-talk.com/medpal-ai-plc-from-zero-to-28-million-annualised-in-ten-months/ *Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*